SABS SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 SAB Biotherapeutics Q2 Earnings Call Highlights SAB Biotherapeutics (NASDAQ:SABS) said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter of 2026, with top-line data expected in the second half of 2027. Chief Executive Officer Samuel Rei | ||
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... Company on track to complete SAFEGUARD enrollment in Q4 2026 while expanding its pipeline with the PRIZE-HAPG study. | ||
 SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 that could triple. On July 7, SAB Biotherapeutics Inc. (NASDAQ:SABS) and Breakthrough T1D, a leading research and advocacy firm for type 1 diabetes, disclosed that Breakthrough T1D has awarded a research grant to Michael J. Haller, M.D., Chief Pediatric Endocrinologist and Professor […] | ||